0819 Filgotinib CRL
BioCentury & Getty Images

Product Development

Filgotinib setback a blow to building franchise around Gilead-Galapagos therapy

Aug 19, 2020 | 11:29 PM GMT

After a surprise setback at FDA for filgotinib in rheumatoid arthritis caused Galapagos to lose more than $3 billion in market cap, two investors who spoke with BioCentury questioned whether the JAK inhibitor still had a chance to compete on the market in RA, ulcerative colitis and other autoimmune indications.  

Polar Capital’s David Pinniger had a grim outlook for the future

Read the full 802 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE